Heron Therapeutics (HRTX) Stock
Small cap biopharma for oncology supportive care and pain. Here's the price, business snapshot, and what's worth knowing about Heron Therapeutics in August 2026.
Heron Therapeutics, Inc. (HRTX) is a small‑cap biopharmaceutical company focused on developing and commercialising treatments for supportive care in oncology and acute pain management. The company has pursued a mix of marketed products and partnered programmes aimed at reducing chemotherapy‑related side effects and improving postsurgical pain control. With a market capitalisation of approximately $238.3 million, Heron operates in a high‑volatility, data‑driven sector where clinical results, regulatory actions and commercial uptake can materially affect valuation. Revenue streams for firms of this size are often lumpy and may rely on licensing deals or collaborations; additional capital raises are not uncommon. This summary is educational and not personalised investment advice — potential investors should review the latest financial statements, regulatory filings and investor presentations, and consider their risk tolerance and diversification needs before acting.
About This Stock
HERON THERAPEUTICS INC
HRTX
Current Price
$0.31
Potential 12 Month Profit
1,432.57%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Ticker
HRTX
Market Cap
$61.34M
Potential 12 Month Profit
1,432.57%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Heron Therapeutics' stock, expecting its price to rise significantly.
Financial Health
Heron Therapeutics is generating good revenue and cash flow, indicating a positive financial outlook.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Catalyst Watch
Upcoming clinical readouts and regulatory milestones can move the share price; positive data may lift sentiment, though trial outcomes are uncertain.
Commercial & Partnerships
Revenue often depends on product uptake and licensing deals; partnerships can broaden reach but terms and milestone risks vary.
Small‑cap Volatility
With a market cap near $238M, liquidity can be limited and price swings larger than for bigger peers; consider diversification and risk tolerance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.